Sculptor Capital’s Rigel Pharmaceuticals RIGL Stock Holding History

Sculptor Capital’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-1,060	Closed	-$25K	–	516
2020 Q3	$25K	Buy	+1,060	New	+$26K	﹤0.01%	335

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Sculptor Capital's RIGL Position: Q4 2020 in Review

Sculptor Capital sold out of Rigel Pharmaceuticals (RIGL) in Q4 2020, closing a stake of 1,060 shares — an estimated $25K sold.

Sculptor Capital first reported a position in RIGL in Q3 2020 and held it in 1 quarter. The position peaked at $25K in Q3 2020. 149 funds tracked by Wall St. Rank hold RIGL as of Q4 2020.

Sculptor Capital reported no remaining Rigel Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Sculptor Capital sold 1,060 Rigel Pharmaceuticals shares in Q4 2020, an estimated $25K.
Sculptor Capital first reported a position in Rigel Pharmaceuticals in Q3 2020 and held it in 1 quarter.
Sculptor Capital's Rigel Pharmaceuticals position peaked at $25K in Q3 2020.
149 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2020.

Based on Sculptor Capital's 13F filing for Q4 2020, filed 16 Feb 2021.